Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Clinical Benefit Sustained in AIDS-Related Kaposi’s Sarcoma Patients Treated With Pegylated Liposomal Doxorubicin

July 1, 2002
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 7
Volume 11
Issue 7

MOUNTAIN VIEW, California-Pegylated liposomal doxorubicin (Doxil, Caelyx) offered a sustained clinical benefit to 37% of patients with AIDS-related Kaposi’s sarcoma vs 16% of patients treated with liposomal daunorubicin (DaunoXome) in a randomized trial comparing the two drugs (ASCO abstract 1640).

MOUNTAIN VIEW, California—Pegylated liposomal doxorubicin (Doxil, Caelyx) offered a sustained clinical benefit to 37% of patients with AIDS-related Kaposi’s sarcoma vs 16% of patients treated with liposomal daunorubicin (DaunoXome) in a randomized trial comparing the two drugs (ASCO abstract 1640).

"In the setting of Kaposi’s sarcoma, clinicians have wondered whether tumor response is correlated with clinically significant improvement," said study investigator Francis Martin, PhD, of Alza Pharmaceuticals in Mountain View, California. "Although the Food and Drug Administration has approved Doxil in Kaposi’s sarcoma on the basis of tumor regression, they also want to know the association between tumor response and benefit to the patients."

In this phase IV, double-blind, multicenter study, 80 patients with AIDS-related Kaposi’s sarcoma were randomized 3:1 to one of two active treatments, either pegylated liposomal doxorubicin at 20 mg/m², or liposomal daunorubicin at 40 mg/m², every 2 weeks for up to six cycles. Baseline characteristics were well balanced, and most patients had newly diagnosed Kaposi’s sarcoma.

Clinical Benefit Shown

Clinical benefit was defined as improvement in at least one of five symptom categories associated with Kaposi’s sarcoma: edema, pulmonary involvement, gastrointestinal involvement, disfiguring lesions, and pain. The final analysis used a more conservative definition of sustained clinical benefit, defined as a sustained improvement lasting at least 28 days in at least one symptom category without worsening of the other symptoms.

Each patient made a biweekly assessment of the five symptom categories using an 11-item questionnaire. An independent blinded reviewer evaluated photographs for disfiguring lesions and edema.

"On the basis of a patient-reported outcomes questionnaire, this study did show that Doxil was associated with improvement in pain, disfiguring lesions, gastrointestinal disease, pulmonary disease, and lymphedema," said study investigator Margaret Tonda, PharmD, of Alza Pharmaceuticals. "Often pain relief is linked to improvement in lymphedema, as obstructed lymphatic drainage by Kaposi’s lesions can cause pain in the feet." In addition to presenting the study results, Dr. Martin and Dr. Tonda offered ONI their perspectives on the trial.

Clinical benefit in at least one of the five symptom categories occurred in 48 (80%) of patients receiving pegylated liposomal doxorubicin and in 12 (63%) of patients receiving liposomal daunorubicin. Sustained improvement in at least one Kaposi’s sarcoma symptom category without worsening of other symptoms occurred in 22 (37%) of patients receiving pegylated liposomal doxorubicin and in 3 (16%) of patients receiving liposomal daunorubicin.

"Not only was Doxil more effective than DaunoXome, but it was effective at about half the dose-equivalent of doxorubicin," Dr. Martin said. "Benefits occur at half the relative dose, allowing patients to remain on treatment longer. Some patients have remained on Doxil for 2 years."

Partial tumor response occurred in 55% of patients receiving pegylated liposomal doxorubicin and in 32% of those receiving liposomal daunorubicin, with a positive correlation between response and transient or sustained clinical benefit. Among patients receiving pegylated liposomal doxorubicin who showed a partial tumor response, 92% experienced a transient clinical benefit, and 42% experienced a sustained clinical benefit lasting at least 28 days. Among those receiving liposomal daunorubicin who showed a partial tumor response, 83% experienced a transient and 33% a sustained clinical benefit.

Photographs showed improvement in 35% of patients treated with pegylated liposomal doxorubicin and 38% of patients treated with liposomal daunorubicin.

Most Toxicities Hematologic

"In general, Doxil is well tolerated," Dr. Martin said. "Toxicities are primarily hematologic, as would be expected from doxorubicin."

Although no new safety issues were identified, 92% of patients on pegylated liposomal doxorubicin and 90% of patients on liposomal daunorubicin experienced adverse events, most commonly neutropenia, nausea, asthenia, anemia, and paresthesia. Discontinuations due to adverse events occurred in four patients receiving pegylated liposomal doxorubicin (5%), including one with treatment-related sepsis. None of the patients receiving liposomal daunorubicin had to discontinue treatment.

Dr. Martin said that pegylated liposomal doxorubicin has been used as the first-line systemic therapy of choice since FDA approval in 1995, even though recent studies suggest that the incidence of Kaposi’s sarcoma has declined since the era of highly active antiretroviral therapy. "Having an effective treatment is still important because Kaposi’s sarcoma can be aggressive, disfiguring, and in some cases invade the viscera," he said.

"Although the incidence of Kaposi’s sarcoma decreased with the adoption of highly active antiretroviral therapy, recent statistics suggest that it is on the rise again," Dr. Tonda said.

Articles in this issue

Translational Research, Early Clinical Trials Support Xeloda/RT in GI Cancers
Capecitabine Research Points to New Combinations for Metastatic Breast Cancer
Good Activity for Capecitabine Confirmed in European Study
European Data Support Benefit of Capecitabine/Irinotecan Regimen in Advanced Colorectal Cancer Patients
Single-Agent Capecitabine May Benefit Elderly Colorectal Cancer Patients
Single-Agent Sequential Rx May Be Reasonable for Metastatic Breast Cancer
Intermittent R115777 Equally Effective but Better Tolerated in Breast Cancer Patients
Carboplatin/Vinorelbine/Capecitabine Active in Pretreated Metastatic Breast Cancer
Longer Survival With FOLFOX4 in Metastatic Colorectal Cancer Patients
Capecitabine/Vinorelbine Effective in Heavily Pretreated Patients
Oral Regimen of UFT/Leucovorin and Etoposide Shows Promising Results
Docetaxel/Capecitabine Bests Single-Agent Docetaxel in Metastatic Breast Cancer
COX-2 Inhibitor May Boost Capecitabine Response
Celecoxib Added to IFL Reduces Toxicity in Patients With Metastatic Colorectal Cancer
Irinotecan Every 2 Weeks With Capecitabine Is Well Tolerated
Recent Videos
Accelerated approval of afami-cel may expand access to therapy for patients who are unable to live near certain treatment centers.
Treatment with afami-cel may offer improved quality of life to patients with metastatic synovial sarcoma compared with continuous chemotherapy.
The difference in adverse effect profiles between sorafenib and nirogacestat may make one treatment more appealing than the other for certain patients with desmoid tumors, says Brian Van Tine, MD, PhD.
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Future developments in the sarcoma space may also involve research on circulating tumor DNA and metabolic therapies, according to Brian Van Tine, MD, PhD.
Current research in the sarcoma space includes the development of treatment options such as T-cell therapies, and combinations such as TKIs/immunotherapy, according to Brian Van Tine, MD, PhD.
Brian Van Tine, MD, PhD, states that sitravatinib appears to be active and well tolerated among patients with dedifferentiated or well-differentiated liposarcoma.
Brian Van Tine, MD, PhD, also discusses how the treatment of desmoid tumors has evolved following data supporting the use of sorafenib in this population.
CAR T-cell therapies and immunotherapy agents may offer up new options and even become standard of care in certain sarcoma subtypes.
There are several novel treatments that may be beneficial in several sarcoma subtypes including CAR T-cell therapies and immune checkpoint inhibitors, according to Sandra P. D’Angelo, MD.
Related Content
Advertisement

Eftilagimod Alfa/Pembrolizumab/RT Elicit Pathologic Responses in Sarcoma

Eftilagimod Alfa/Pembrolizumab/RT Elicit Pathologic Responses in Sarcoma

Tim Cortese
May 29th 2025
Article

Eftilagimod alfa with pembrolizumab and radiotherapy exceeded the median tumor hyalinization/fibrosis vs historical benchmarks in resectable soft tissue sarcomas.


Brian A. Van Tine, MD, PhD, discusses potential evolutions in the treatment landscape following the FDA approval of afami-cel in metastatic synovial sarcoma.

Afami-cel Approval May Open Gateway for Synovial Sarcoma Advancements

Brian Van Tine, MD, PhD
August 26th 2024
Podcast

Brian A. Van Tine, MD, PhD, discusses potential evolutions in the treatment landscape following the FDA approval of afami-cel in metastatic synovial sarcoma.


3 Things You Should Know About Individualizing Care for Patients With Epithelioid Sarcoma

3 Things You Should Know About Individualizing Care for Patients With Epithelioid Sarcoma

ONCOLOGY Staff
April 18th 2025
Article

Personalized therapeutic approaches and novel, targeted medicines can help patients with epithelial sarcoma attain better survival outcomes.


Brian Van Tine, MD, PhD, speaks about several agents and combination regimens that are currently under investigation in the sarcoma space, and potential next steps in research including immunotherapies and vaccine-based treatments.

Sarcoma Awareness Month 2023 with Brian Van Tine, MD, PhD

Brian Van Tine, MD, PhD
August 1st 2023
Podcast

Brian Van Tine, MD, PhD, speaks about several agents and combination regimens that are currently under investigation in the sarcoma space, and potential next steps in research including immunotherapies and vaccine-based treatments.


3 Things You Should Know About Identifying and Treating Epithelioid Sarcoma

3 Things You Should Know About Identifying and Treating Epithelioid Sarcoma

ONCOLOGY Staff
February 19th 2025
Article

Experts discuss epithelioid sarcoma diagnosis, management, and targeted therapies, and highlight 3 things everyone should know about treatment.


The phase 3 INVINCIBLE-3 trial is evaluating INT230-6 vs standard of care in locally recurrent, inoperable, or metastatic soft tissue sarcoma.

Data Monitoring Committee OKs INVINCIBLE-3 Sarcoma Trial Continuation

Roman Fabbricatore
January 28th 2025
Article

The phase 3 INVINCIBLE-3 trial is evaluating INT230-6 vs standard of care in locally recurrent, inoperable, or metastatic soft tissue sarcoma.

Related Content
Advertisement

Eftilagimod Alfa/Pembrolizumab/RT Elicit Pathologic Responses in Sarcoma

Eftilagimod Alfa/Pembrolizumab/RT Elicit Pathologic Responses in Sarcoma

Tim Cortese
May 29th 2025
Article

Eftilagimod alfa with pembrolizumab and radiotherapy exceeded the median tumor hyalinization/fibrosis vs historical benchmarks in resectable soft tissue sarcomas.


Brian A. Van Tine, MD, PhD, discusses potential evolutions in the treatment landscape following the FDA approval of afami-cel in metastatic synovial sarcoma.

Afami-cel Approval May Open Gateway for Synovial Sarcoma Advancements

Brian Van Tine, MD, PhD
August 26th 2024
Podcast

Brian A. Van Tine, MD, PhD, discusses potential evolutions in the treatment landscape following the FDA approval of afami-cel in metastatic synovial sarcoma.


3 Things You Should Know About Individualizing Care for Patients With Epithelioid Sarcoma

3 Things You Should Know About Individualizing Care for Patients With Epithelioid Sarcoma

ONCOLOGY Staff
April 18th 2025
Article

Personalized therapeutic approaches and novel, targeted medicines can help patients with epithelial sarcoma attain better survival outcomes.


Brian Van Tine, MD, PhD, speaks about several agents and combination regimens that are currently under investigation in the sarcoma space, and potential next steps in research including immunotherapies and vaccine-based treatments.

Sarcoma Awareness Month 2023 with Brian Van Tine, MD, PhD

Brian Van Tine, MD, PhD
August 1st 2023
Podcast

Brian Van Tine, MD, PhD, speaks about several agents and combination regimens that are currently under investigation in the sarcoma space, and potential next steps in research including immunotherapies and vaccine-based treatments.


3 Things You Should Know About Identifying and Treating Epithelioid Sarcoma

3 Things You Should Know About Identifying and Treating Epithelioid Sarcoma

ONCOLOGY Staff
February 19th 2025
Article

Experts discuss epithelioid sarcoma diagnosis, management, and targeted therapies, and highlight 3 things everyone should know about treatment.


The phase 3 INVINCIBLE-3 trial is evaluating INT230-6 vs standard of care in locally recurrent, inoperable, or metastatic soft tissue sarcoma.

Data Monitoring Committee OKs INVINCIBLE-3 Sarcoma Trial Continuation

Roman Fabbricatore
January 28th 2025
Article

The phase 3 INVINCIBLE-3 trial is evaluating INT230-6 vs standard of care in locally recurrent, inoperable, or metastatic soft tissue sarcoma.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.